-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40

Benzinga·10/12/2026 17:41:02
Diffusion vocale
BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform and lowers the price target from $47 to $40.